Suppr超能文献

顺铂-5-氟尿嘧啶与吉西他滨-顺铂两种治疗方案在胆囊癌患者中的对比研究

Comparative Study Between Two Treatment Regimens of Cisplatin-5-Fluorouracil and Gemcitabine-Cisplatin in Gallbladder Cancer Patients.

作者信息

Ali Daud, Alam Nawazish, Yasmin Farhat, Ali Sajid, Anwer Tarique, Alam Sarfaraz, Ahmad Sarfaraz

机构信息

Departmentof Pharmacy Practice, National Institute of Pharmaceutical Education & Research, Hajipur, India.

Collegeof Pharmacy, Jazan University, Jazan, KSA.

出版信息

Iran J Pharm Res. 2017 Spring;16(2):798-804.

Abstract

The research study was designed to compare the safety and efficacy of the regimen of 5-flurouracil with cisplatin of investigational armwith the reference regimen of gemcitabine with cisplatin for the treatment of gallbladder cancer.Atotal of 60 patients were enrolled in the study.Out of 30 patients enrolledinarm-A (Gemcitabine withCisplatin) and 30 patients enrolledin arm-B (5-Flurouracilwith Cisplatin) for safety assessment. For the efficacy evaluation total of 16 patients enrolled which is equally divided in both arm.Total 150 cycles of chemotherapy were given to each arm of patients. Both armswere well balanced with respect to age, stage of disease and measurability.The overall response rate (ORR) was 62.5% in arm-A compared to 50% in arm-B (p = 0.34). Whereas 95% confidence interval (CI) for the efficacy was found 46.25-8.74%32.67-67.32% between arm-A and arm-B.The most prevalent toxicities were found anemia (p < 0.05), neutropenia (p < 0.05) leucopenia (p<0.05) and thrombocytopenia (p < 0.05) and it occurred at a higher rate in arm-B than in arm-A of various grades.There was no statistically significant efficacy & toxicity for gemcitabine and cisplatin with 5-flurouracil and cisplatin however there was an overall more benefit in arm-A patients than arm-B patients.

摘要

该研究旨在比较研究组中5-氟尿嘧啶与顺铂联合方案和吉西他滨与顺铂联合的对照方案治疗胆囊癌的安全性和疗效。共有60名患者参与了该研究。为进行安全性评估,30名患者入组A组(吉西他滨与顺铂联合),30名患者入组B组(5-氟尿嘧啶与顺铂联合)。为进行疗效评估,共入组16名患者,两组各半。每组患者均接受了150个周期的化疗。两组在年龄、疾病分期和可测量性方面平衡良好。A组的总缓解率(ORR)为62.5%,而B组为50%(p = 0.34)。A组和B组疗效的95%置信区间(CI)分别为46.25 - 8.74%和32.67 - 67.32%。最常见的毒性反应为贫血(p < 0.05)、中性粒细胞减少(p < 0.05)、白细胞减少(p < 0.05)和血小板减少(p < 0.05),且B组各等级毒性反应的发生率均高于A组。吉西他滨与顺铂联合方案和5-氟尿嘧啶与顺铂联合方案在疗效和毒性方面无统计学显著差异,但总体而言,A组患者比B组患者获益更多。

相似文献

引用本文的文献

本文引用的文献

2
Global cancer statistics.全球癌症统计数据。
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4.
10
Cholangiocarcinoma: current concepts and insights.胆管癌:当前概念与见解
Hepatology. 2003 May;37(5):961-9. doi: 10.1053/jhep.2003.50200.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验